scholarly journals High Expression of Nucleobindin-2 Is Associated With Poor Prognosis in Gastric Cancer

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A1021-A1021
Author(s):  
Junichi Okada ◽  
Eijiro Yamada ◽  
Tsugumichi Saito ◽  
Yasuyo Nakajima ◽  
Atsushi Ozawa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Leucine Zipper ◽  
Independent Predictor ◽  
Clinical Stage ◽  
High Expression ◽  
Peripheral Tissues ◽  
Tumor Tissues ◽  
Gastric Cancer Patients ◽  
Cancer Tissues

Abstract Nucleobindin-2 (NUCB2) is a 396-amino acid protein, cleaved into the N-terminal nesfatin-11-82, nesfatin-285-163 and the C-terminal nesfatin-3166-396. NUCB2 contains a signal peptide, a leucine zipper structure, two Ca2+ binding EF-hand domains, and has a wide variety of basic cellular functions. NUCB2 is also a precursor protein of nesfatin-1, which was originally identified in hypothalamic nuclei, and which is a regulatory factor involved in the central control of food intake and energy balance. There are several reports indicating that NUCB2 is also expressed in various human peripheral tissues. Moreover, recent studies have reported that high levels of NUCB2 mRNA and protein are a potent prognostic factor for prostate cancer, endometrial carcinoma, and breast cancer. NUCB2 was also identified as a potential tumor antigen eliciting autoantibody responses in 5.4% of gastric cancer patients but not in the healthy individuals. However, theclinicopathological significance of NUCB2 expression in gastric cancer has still not been elucidated. Therefore, we examined NUCB2 expression in a large number of gastric cancer patients, using immunohistochemistry, to explore its clinicopathological significance. To explore this, we aimed to investigate the NUCB2 expression in gastric cancer tissues and adjacent non-tumor tissues and its potential relevance to clinicopathological factors and prognosis using immunohistochemistry analysis. In our study, NUCB2 level in gastric cancer tissues was higher than in non-tumor tissues. A high expression of NUCB2 is significantly associated with tumor depth, lymph node metastasis, lymphatic invasion, venous invasion and clinical stage. Furthermore, the expression level of NUCB2 protein was independent predictor of progression-free survival. In summary, NUCB2 might play a crucial role in gastric cancer development and could serve as an independent predictor of prognosis of gastric cancer patients.

The Clinicopathological Significance and Prognostic Value of Obg-Like Atpase 1 (OLA1) in Gastric Cancer

2021 ◽  
Author(s):  
Juan Wang ◽  
Zihan Zheng ◽  
Qinghua Cao ◽  
Xiufen Liu ◽  
Zhiqing Wang
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Biological Significance ◽  
High Expression ◽  
Cancer Tissue ◽  
Cox Regression Analysis ◽  
Gastric Cancer Patients ◽  
Cancer Tissues

Abstract Backgroud Obg-like ATPase 1 (OLA1) is a member of the Obg family of P-loop NTPases and has recently been detected in several human cancer cells. However, its expression type and clinical relevance in gastric cancer remains unclear. Methods In the present study, 2 datasets downloaded from the open Gene Expression Omnibus database were used to evaluate the mRNA level of OLA1 in gastric cancer. Quantitative Reverse Transcription PCR further validated the mRNA expression in gastric cancer tissues. Immunohistochemistry was performed on gastric cancer tissue microarray to assess OLA1 protein expression type, prognostic value, biological significance and its association with Snail in 334 patients of gastric cancer. The prognostic value of combination of OLA1 and Snail has been evaluated. Results The results showed that OLA1 mRNA and protein were elevated in gastric cancer tissues. High expression of OLA1 was significantly associated with aggressive features, such as tumor size, lymph node metastasis and TNM stage (P = 0.0146, P = 0.0037, P < 0.001, respectively). Moreover, high levels of OLA1 predicted worse overall survival. Multivariate Cox regression analysis indicated that high expression of OLA1 was an independent prognostic factor for poor overall survival (hazard ratio, 0.573; 95% confidence interval, 0.376–0.872; P = 0.009). Additionally, OLA1 expression was positively correlated with Snail, and combination of them revealed improved prognostic accuracy for gastric cancer patients. Conclusions Our results suggested that OLA1 high expression was considered as an independent factor for the prediction of unfavorable prognosis in gastric cancer patients, and we believe that OLA1 could serve as a biomarker of poor prognosis and a novel target in treating gastric cancers.

scholarly journals Low Expression of PDHX is Associated with Poor Prognosis and Immune Infiltration in Gastric Cancer

2021 ◽  
Author(s):  
Biao Sun ◽  
Bao Li ◽  
Ziyang Long ◽  
Cangyuan Zhang ◽  
Qiannan Sun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Survival Time ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Pyruvate Dehydrogenase ◽  
High Expression ◽  
Immune Infiltration ◽  
Gastric Cancer Patients ◽  
Cancer Tissues

Abstract Background: Pyruvate dehydrogenase protein X (PDHX) is a non-catalytic subunit of the pyruvate dehydrogenase (PDH) complex. It is located in the center of mitochondrial energy metabolism and is an essential component to maintain the biological activity of PDH complex. The purpose of this study was to explore its expression level in gastric cancer and its relationship with immune infiltration. Methods: Through immunohistochemical analysis of 80 pairs of gastric cancer tissue samples and open database analys such as Kaplan-Meier Plotter, TIMER2.0,GEPIA,String and DAVID database.Results: We found that the expression of PDHX in paracancerous tissues was significantly higher than that in gastric cancer tissues. Database analysis showed that the expression of PDHX was low in gastric cancer tissues, and the total survival time (OS) of relatively high expression in gastric cancer patients was higher. In N1~N3 and M stages, the P values of OS and PFS with high expression of PDHX were less than 0.05. It is suggested that the overexpression of PDHX may affect the prognosis of gastric cancer patients with lymph node and distant metastasis. Conclusions: Therefore, we concluded that the expression of PDHX is suppressed in gastric cancer and has a longer overall survival time of 5 years in patients with relatively high expression, and that the increased expression of PDHX may improve the prognosis of patients with lymph node and distant metastasis of gastric cancer.

Evaluation of the Safety and Feasibility of Laparoscopic Total Gastrectomy in Clinical Stage I Gastric Cancer Patients

2015 ◽  
Vol 39 (7) ◽  
pp. 1782-1788 ◽  
Author(s):  
Daisuke Ichikawa ◽  
Shuhei Komatsu ◽  
Takeshi Kubota ◽  
Kazuma Okamoto ◽  
Hirotaka Konishi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Total Gastrectomy ◽  
Clinical Stage ◽  
Laparoscopic Total Gastrectomy ◽  
Stage I ◽  
Gastric Cancer Patients

scholarly journals Down-regulation of HIF-1α inhibits the proliferation, migration, and invasion of gastric cancer by inhibiting PI3K/AKT pathway and VEGF expression

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Jingjing Zhang ◽  
Jun Xu ◽  
Yonghong Dong ◽  
Bo Huang
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Akt Pathway ◽  
Migration And Invasion ◽  
Vegf Expression ◽  
Gastric Cancer Cells ◽  
Tumor Tissues ◽  
Sirna Silencing ◽  
Gastric Cancer Patients

In view of the high incidence of gastric cancer and the functions of hypoxia-inducible factor 1α (HIF-1α), our study aimed to investigate the functionality of HIF-1α in gastric cancer, and to explore the diagnostic and prognostic values of HIF-1α for this disease. Expression of HIF-1α in tumor tissues and adjacent healthy tissues as well as serum collected from both gastric cancer patients and normal healthy controls was detected by qRT-PCR. Survival analysis was performed using Kaplan–Meier method. HIF-1α siRNA silencing cell lines were established. Effects of HIF-1α siRNA silencing as well as PI3K activator sc3036 on proliferation, migration, and invasion of gastric cancer cells were detected by Cell counting kit (CCK-8) assay, and Transwell migration and invasion assay. Effects of HIF-1α siRNA silencing on AKT and VEGF were detected by Western blot. Expression of HIF-1α was significantly down-regulated in tumor tissues than in adjacent healthy tissues in most gastric cancer patients. Serum levels of HIF-1α were also higher in gastric cancer patients than in normal healthy people. Serum HIF-1α showed promising diagnostic and prognostic values for gastric cancer. HIF-1α siRNA silencing inhibited the proliferation, migration, and invasion of gastric cancer cells, while PI3K activator sc3036 treatment reduced those inhibitory effects. Down-regulation of HIF-1α can inhibit the proliferation, migration, and invasion of gastric cancer possibly by inhibiting PI3K/AKT pathway and VEGF expression.

Aberrantly Expressed Recoverin in Tumor Tissues from Gastric Cancer Patients

2003 ◽  
pp. 173-176
Author(s):  
Yasuhiro Miyagawa ◽  
Hiroshi Ohguro ◽  
Ikuyo Maruyama ◽  
Yoshiko Takano ◽  
Hitoshi Yamazaki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Tumor Tissues ◽  
Gastric Cancer Patients

Preoperative factors predictive of pathologic upstaging in clinical stage I gastric cancer patients.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 39-39
Author(s):  
Hayavadhan Thuppal ◽  
Patricia Friedmann ◽  
John Christopher McAuliffe ◽  
Peter Muscarella ◽  
Haejin In
Keyword(s):  
Risk Factors ◽  
Gastric Cancer ◽  
Logistic Regression ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Clinical Stage ◽  
Gastric Cancer Patients ◽  
Stage 1

39 Background: In patients with stage 1 gastric cancer, surgical resection without neoadjuvant therapy is offered as the first line treatment. However, some of these patients are found to have higher stage after resection and miss the opportunity for neoadjuvant therapy. Preoperative patient and tumor characteristics may be predictive of the likelihood of pathological upstaging in stage 1 gastric cancer patients who have not received neo-adjuvant therapy. Methods: The National Cancer Database was queried for patients diagnosed from 2004-2015 with clinical stage 1 gastric adenocarcinoma who had undergone surgical resection without neoadjuvant therapy. Univariate analysis and multivariable logistic regression were conducted to determine pre-operative factors associated with pathological upstaging. Candidate variables examined included age, sex, race, tumor size, histology, grade, tumor location, days to surgery, and lymphovascular invasion. Results: Analysis was conducted on 8,015 clinical stage 1 patients. Overall 1,981 (25%) patients were upstaged. On multivariable logistic regression analysis, significant predictors of upstaging included increasing tumor size [ref : size < 1 cm, 1-2 cm aOR=3.8 (95% CI 2.3-6.1); 2-4 cm aOR=12.4 (7.9-19.5); > = 4cm aOR=25.9 (22.9-56.4)], younger age [ref: > = 75, < 50 aOR=1.7 (1.4-2.1), 50-65 aOR=1.4 (1.2-1.6), 65-75 aOR=1.2 (1.1-1.5)], male gender [aOR=1.16 (1.0-1.3)], presence of diffuse type gastric cancer [aOR=2.3 (1.7-3.2)], mucinous type [aOR=1.7 (1.1-2.5)], or signet ring cell histology [aOR=1.6 (1.3-2.0)] compared to intestinal histology, presence of lymphovascular invasion [aOR=6.0 (5.0-7.1)], and increasing grade [ref: grade 1, grade 2 aOR=2.30 (1.7-3.5); grade 3 aOR=4.9 (3.6- 6.7)]. Conclusions: A quarter of all patients thought to have stage 1 gastric cancer prior to surgery had higher pathologic stage at time of resection. Patients with the above risk factors may be understaged with currently available diagnostic tools. The addition of neoadjuvant therapy should be considered when the above risk factors are present in clinical stage 1 patients.

Sign in / Sign up

Export Citation Format

Share Document